Table 2 |
|||||
|
Sensitivity, specificity, 95% confidence intervals and likelihood ratios |
|||||
| Sensitivity |
Specificity |
Likelihood ratio |
|||
|
|
|||||
| % |
95% CI |
% |
95% CI |
||
|
|
|||||
| PTPN22 CT+TT |
39.3 |
29.6–49.7 |
80.3 |
75.9–84.1 |
2.0 |
| Anti-CCP Abs |
37.1 |
27.5–47.5 |
98.6 |
96.9–99.5 |
26.2 |
| IgG-RF |
16.9 |
8.9–28.1 |
95.8 |
92.6–97.8 |
4.0 |
| IgA-RF |
42.4 |
30.3–55.2 |
94.9 |
91.5–97.2 |
8.3 |
| IgM-RF |
22.0 |
12.8–33.9 |
94.1 |
90.5–96.6 |
3.7 |
| SE (B1*0404 or 0401) |
55.6 |
45.2–65.6 |
61.8 |
54.4–68.9 |
1.5 |
| SE + PTPN22 CT+TT |
24.1 |
16.0–34.0 |
92.9 |
88.3–96.1 |
3.4 |
| Anti-CCP Abs + PTPN22 CT+TT |
22.1 |
14.3–31.8 |
100.0 |
- |
- |
|
|
|||||
|
Sensitivity, specificity, 95% confidence intervals (CIs) and likelihood ratios were determined for the presence of the PTPN22 1858T variant (CT+TT), anti-cyclic citrullinated peptide antibodies (anti-CCP Abs), rheumatoid factors IgM-RF, IgG-RF and IgA-RF, and carriage of human leukocyte antigen shared epitope (HLA-SE) in pre-patients and matched controls. |
|||||
|
Johansson et al. Arthritis Research & Therapy 2006 8:R19 doi:10.1186/ar1868 |
|||||
